Thinner waistlines, fatter wallets
Latest obesity drugs to generate as much as USD $77 billion in revenue by 2030
Novo Nordisk and Eli Lilly are cashing in big-time on Ozempic and Zepbound —stocks are soaring!
So… should we jump in and invest while it’s hot?
The Trump effect on bonds, crypto, banks, tech and more
What does the latest cut to Interest Rates mean for you?
The “skinny” on Ozempic
In our Wednesday’s newsletter, we dove into the wild world of GLP-1 agonists like Ozempic and Zepbound — once humble diabetes meds, they’re now the A-listers of weight loss. 🏆 Surprisingly, 61% of you are sticking with the OGs: diet and exercise (we see you, kale and kettlebells!). Meanwhile, almost 20% are eyeing or already cozying up to these miracle shots.💉
Research shows these drugs (one injection per week) can help you drop 10% to 20% of your body weight while slashing your calorie intake by half. 🍔🚫 And it doesn’t stop there: people are ghosting their beloved junk food, saying “meh” to happy hour, and even giving up smokes. Why? Because these drugs apparently rewire your brain to stop throwing a party every time you bite into a Krispy Kreme.🍩💔
This week, we're peeling back the layers on how the pharma giants are cashing in on this craze. Is their meteoric rise built to last, or will the hype deflate faster than a bag of chips? Let’s dig into the numbers.📊